The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

Low-income beneficiaries are also feeling the squeeze. Enrollment in the Low-Income Subsidy (LIS) program dropped from 13.7 ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

Don't Be Fooled Throughout the year and especially during Medicare Open Enrollment (Oct 15-Dec 7), plans are actively marketing their products through television ads, social media ads, radio ads, and ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

Thousands of Rhode Island seniors and disabled residents no longer covered for non-emergency visits at four local hospitals ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

The federal government's Medicare program and older adults together spend $4.4 billion a year on care that has low clinical ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

Medicare finalized inpatient pay rates that are slightly higher than those proposed in April. Hospital groups were pleased ...